|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2003-7-11
|
|
pubmed:abstractText |
OSI-774 is an inhibitor of the epidermal growth factor receptor tyrosine kinase (EGFR-TK) currently in clinical development. In preclinical models, the antitumor activity of OSI-774 was directly related to its ability to inhibit the EGFR-TK. On the basis of these data, we hypothesized that inhibition of the EGFR-TK will be required for this agent to be effective in the clinic. This study evaluated the pharmacodynamic effects of OSI-774 in normal skin tissues collected from patients treated with the agent in a Phase I study.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2478-86
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:12855621-Antineoplastic Agents,
pubmed-meshheading:12855621-Humans,
pubmed-meshheading:12855621-Immunohistochemistry,
pubmed-meshheading:12855621-Mitogen-Activated Protein Kinases,
pubmed-meshheading:12855621-Neoplasms,
pubmed-meshheading:12855621-Quinazolines,
pubmed-meshheading:12855621-Receptor, Epidermal Growth Factor,
pubmed-meshheading:12855621-Signal Transduction,
pubmed-meshheading:12855621-Skin,
pubmed-meshheading:12855621-Tyrosine,
pubmed-meshheading:12855621-Up-Regulation
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.
|
|
pubmed:affiliation |
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
|
|
pubmed:publicationType |
Journal Article
|
